Orchestrating the immune Response
TO Defeat Cancer & Infectious Diseases

Engineering precision immunity

Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology  to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.


Lymph nodes:
where the immune response is orchestrated

Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.





Our programs

Elicio’s core business is the  development of therapeutic cancer vaccines. ELI-002, its lead clinical program, is designed to stimulate an immune response against the seven Kirsten rat sarcoma (KRAS) mutations driving 25% of solid tumors. ELI-002 is currently being studied in AMPLIFY-201, a Phase 1 dose escalation study, and AMPLIFY-7P, a Phase 1/2 study.



Latest News

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
BOSTON , Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly , Chief Executive Officer,...  » Read more
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at AACR Special Conference : Pancreatic Cancer ELI-002 2P induced T cell responses correlated with an 86% reduction in the risk of progression or death Both CD4+ and CD8+ T Cells targeting...  » Read more

Elicio title slide corporate presentation September 2023

Elicio Corporate Presentation 

Download this presentation

Presentation title slide: Targeting the Lymph Nodes to Orchestrate Anti-tumor Immunity

Koch Institute Symposium: Targeting the Lymph Nodes to Orchestrate Anti-tumor Immunity

View this presentation